Posted by Michael Wonder on 02 Aug 2023
FDA approves trifluridine and tipiracil with bevacizumab for previously treated metastatic colorectal cancer
2 August 2023 - Today, the FDA approved trifluridine and tipiracil (Lonsurf, Taiho Oncology) with bevacizumab, for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
The FDA had previously approved single-agent Lonsurf for this indication in September 2015.
